AtriCure beats the Street during Q4, analysts predict ‘growth acceleration’


AtriClip Pro-V AtriCure research

The AtriClip Pro-V [Image courtesy of AtriCure]

AtriCure (Nasdaq: ATRC) — an innovator in treatments for atrial fibrillation and left atrial appendage management — is enjoying a rise in its stock value today after releasing results that beat the Street.

Mason, Ohio–based AtriCure’s stock was up 67 cents per share, or 3.7%, closing at $18.99. The company reported yesterday evening that it revenue for the quarter ended Dec. 31 was up nearly 12% year-over-year, to $46.1 million. Analyst polled by Yahoo! Finance had predicted $45.4 million in revenue.

Get the full story on our sister site MassDevice. 

Want to stay on top of MDO content? Subscribe to our e-newsletter.

Speak Your Mind